Evaluation of difluprednate ophthalmic emulsionfor macular edema and neovascular desease

Evaluation of difluprednate ophthalmic emulsionfor macular edema and neovascular desease - Evaluation of difluprednate ophthalmic emulsionfor macular edema and neovascular desease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001432

Enrollment

130

Registered

2010-09-30

Start date

2008-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

macular edema, neovascular eye desease

Interventions

Difluprednate ophthalmic emulsion is instilled 4 times a day for the first month and then twice a day for 2 months.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients with diabetic macular edema and with mean foveal thickness more than 300 micro meter.

Exclusion criteria

Exclusion criteria: The patients with intraocular pressure more than 21 mmHg. Patients diagnosed as steroid responder.

Design outcomes

Primary

Measure	Time frame
Foveal thickness	—

Secondary

Measure	Time frame
Visual acuity	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026